


Specifications



pEGASUS
Stent System


phenox

Compatible with MC 0.0165" / 0.017" ID Microcatheters



REF HPC	Min. Vessel Diameter (mm)	Max. Vessel Diameter (mm)	A: Stent Diameter unconstrained (mm)	B: Stent Length (mm)
pEGASUS-350-15-HPC	2,5	3,5	4,0	15
pEGASUS-350-20-HPC	2,5	3,5	4,0	20
pEGASUS-350-25-HPC	2,5	3,5	4,0	25
pEGASUS-350-30-HPC	2,5	3,5	4,0	30
pEGASUS-450-15-HPC	3,5	4,5	5,0	15
pEGASUS-450-20-HPC	3,5	4,5	5,0	20
pEGASUS-450-25-HPC	3,5	4,5	5,0	25
pEGASUS-450-30-HPC	3,5	4,5	5,0	30

A non-coated bare version is available upon request.



Manufactured by:
femtos
femtos GmbH
Universitätsstraße 136
D-44799 Bochum
Germany
www.femtos.de
Tel. +49 234 970 50 320
Fax +49 234 970 50 327

Distributed by:
phenox
phenox GmbH
Lise-Meitner-Allee 31
D-44801 Bochum
Germany
www.phenox.net
Tel. +49 234 36 919 0
Fax +49 234 36 919 19

Next level aneurysm bridging with HPC coating technology

KIF-0089B

phenox

pEGASUS Stent System

Includes the latest phenox technology Combines flexibility with stability

Key features


- Self-expanding, open-cell stent design for optimal adaptation to different vessel configurations
- Treatment of wide-neck aneurysms, dissections & intracranial stenoses
- Available with the proprietary, antithrombogenic **HPC** coating technology for increased patient safety
- For vessels from 2.5 mm to 4.5 mm
- Compatible with MC 0.0165" / 0.017" ID

A 0.017" MC-compatible Nitinol stent structure coated with phenox' unique antithrombogenic HPC technology - the pEGASUS Stent System allows for the reconstruction of diseased arteries, in particular:

- Saccular and fusiform aneurysms and pseudo-aneurysms in combination with coils
- Vascular dissections in the acute and chronic phases


AND if the stenosed segment is dilated via PTA before:

- Atherosclerotic vascular stenoses of intracranial arteries



Easy positioning is achieved by pEGASUS' unique open cell design that combines flexibility with advanced kink resistance properties. The balanced radial force along the stent body secures anchoring even in very tortuous anatomy - enabling a stable and dense packing of coils. Visibility is achieved by three proximal and three distal markers.

Advanced conformability in complex curvature



The pEGASUS Stent System has received the CE Mark (CE 0297). It is not approved for sale nor is available for sale or use in the United States.

The HPC effect



Less thrombogenic stent surface for increased patient safety

 A detailed diagram comparing the interaction of platelets with a bare metal surface versus an HPC-coated surface. On the left, a 'Bare' surface is shown with a 'Glycocalyx' (natural lining of the endothelium). Platelets are shown with their receptors detecting damages in the vessel wall or foreign bodies, which triggers them to launch a clotting cascade. On the right, the 'with HPC' surface is shown. The HPC coating mimics the glycocalyx, so platelets do not recognize the surface as a foreign body, and systemic blood coagulation is not disturbed.

pEGASUS HPC Stent System
The **HPC** coating mimics the glycocalyx, thus the platelets do not recognize the surface as a foreign body. Systemic blood coagulation is not disturbed.

Platelets
Receptors of platelets detect damages in the vessel wall or foreign bodies. Thus, they can launch the clotting cascade.

Glycocalyx
Natural lining of the endothelium indicating an intact inner vessel wall.

Bare **with HPC**

Representative fluorescence micrographs of uncoated (bare) and HPC-coated nickel titanium specimens. Significantly reduced platelet adhesion can be observed after human blood exposure.

DISCLAIMER: This illustration does not represent actual size proportions.